FGP
AMPH icon

Freestone Grove Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Freestone Grove Partners’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,857
Closed -$585K – 1010
2026
Q1 		$585K Buy
29,857
+2,264
+8% +$55.4K ﹤0.01% 571
2025
Q4 		$739K Buy
+27,593
New +$711K 0.01% 503

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Freestone Grove Partners's AMPH Position: Q2 2026 in Review

Freestone Grove Partners sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 29,857 shares — an estimated $585K sold.

Freestone Grove Partners first reported a position in AMPH in Q4 2025 and held it in 2 quarters. The position peaked at $739K in Q4 2025. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Freestone Grove Partners reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 29,857 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $585K.
  • Freestone Grove Partners first reported a position in Amphastar Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Amphastar Pharmaceuticals position peaked at $739K in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.